National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 5 of 1994)

Overview

The National Health Act 1953 was enacted to provide for the administration of the Pharmaceutical Benefits Scheme (PBS) and to facilitate access to affordable medicines for the Australian population. This Act was introduced to address the gap in providing a structured system for the reimbursement of prescription medications, ensuring that essential medicines were accessible and affordable to all Australians. The enacting body was the Parliament of Australia, and the policy objective was to establish a comprehensive framework for the provision of affordable medicines through the PBS, thereby promoting equitable access to necessary health treatments. This legislative instrument, a declaration under subsection 85 (2AA) of the Act, was made to amend the list of pharmaceutical benefits by excluding certain drugs and medicinal preparations from the PBS, ensuring the scheme's focus remains on effective and necessary treatments.

Scope and Application

The Declaration under subsection 85 (2AA) of the National Health Act 1953 applies to specific drugs and medicinal preparations listed in the Schedule, which effectively removes their eligibility for benefits under Part VII of the Act. The named medications, such as "Banish" and "Super Banish," will no longer qualify for the Pharmaceutical Benefits Scheme (PBS) from the date of operation of this Declaration, which is 1 April 1994. The application of this legislative instrument is limited to the entities and individuals whose medications are specified in the Schedule, thereby directly affecting those who rely on these drugs for their healthcare needs. The jurisdictional reach of this Declaration is national, as it pertains to the Commonwealth of Australia and its administration of the PBS. There are no exclusions, exemptions, or thresholds stated within the text of this Declaration; however, the Act may extend or restrict its application through subordinate instruments. This legislative instrument is an example of how the Commonwealth can modify the list of substances eligible for pharmaceutical benefits under the National Health Act 1953.

Key Provisions

The key operative sections of the declaration under subsection 85(2AA) of the National Health Act 1953, as made by David Trevor Graham, Assistant Secretary of the Pharmaceutical Benefits Branch, specify the cessation of certain drugs and medicinal preparations from being covered under Part VII of the Act. According to section 1 of the Declaration, the effective date for these changes is 1 April 1994. Section 2 details the specific drugs and preparations listed in the Schedule, which will no longer be subject to the provisions of Part VII of the Act. The obligations imposed by this Act primarily concern the Pharmaceutical Benefits Branch and the Department of Human Services and Health. The Assistant Secretary, acting as the Delegate of the Minister for Health, is required to consult with the Pharmaceutical Benefits Advisory Committee and make a formal declaration in accordance with subsection 85(2AA) of the Act. This process ensures that the decision to delist certain drugs and preparations is made with due consideration of expert advice. Failure to comply with the provisions of the Act may result in legal consequences. While the Act itself does not explicitly detail offences, penalties, or specific consequences for breaches, the broader legislative framework under which the Act operates could imply various penalties. These might include fines, imprisonment, or other civil or administrative penalties depending on the nature and severity of the breach. The maximum penalties would be determined by the relevant sections of the primary legislation or subsidiary legislation that applies to the specific context of the breach.